Shu-Yen Chang

Title: Shu-Yen Chang: Innovator in Therapeutic Antibodies

Introduction

Shu-Yen Chang is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of 4 patents to his name, his work focuses on innovative solutions for cancer treatment.

Latest Patents

Chang's latest patents involve humanized antibodies and antigen-binding fragments that specifically target biantennary Lewis antigens. These antigens are expressed in various cancers, making his inventions crucial for both treatment and detection of these diseases. The disclosed antibodies are designed to target antigen-expressing cells, providing a method for effective disease management. Additionally, his patents include polynucleotides, vectors, and host cells for producing these antibodies, along with pharmaceutical compositions and methods for treatment and detection.

Career Highlights

Shu-Yen Chang is currently associated with Glyconex, Inc., where he continues to advance his research in therapeutic antibodies. His work has the potential to significantly impact cancer therapies and improve patient outcomes.

Collaborations

Chang collaborates with notable colleagues, including Tong-Hsuan Chang and Jerry Ting, to further enhance the development of innovative therapeutic solutions.

Conclusion

Shu-Yen Chang's contributions to the field of therapeutic antibodies exemplify the importance of innovation in medical science. His work not only advances the understanding of cancer treatment but also paves the way for future breakthroughs in biotechnology.